Virtual Library
Start Your Search
Y. Wen
Author of
-
+
P2.01 - Advanced NSCLC (ID 618)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 10/17/2017, 09:00 - 16:00, Exhibit Hall (Hall B + C)
-
+
P2.01-029 - Real World Report of Clinical Outcomes of Bevacizumab in First-Line or Later-Line Treatment for Patients with Advanced NSCLC (ID 8999)
09:00 - 09:00 | Author(s): Y. Wen
- Abstract
Background:
Bevacizumab combined therapy has been demonstrated superior efficacy and well tolerability in first-line and later-line treatment by various scales of prospective control trials. But it is still lack of direct evidence endorsing bevacizumab as first-line (1L) over later-line (LL) use.
Method:
We retrospectively evaluated the effectiveness of bevacizumab contained therapy as 1L or LL treatment in patients with advanced NSCLC. Primary outcome was progression-free survival (PFS), and the secondary objectives were objective response rate (ORR), disease control rate (DCR) and safety. Subsequently, an exploratory analysis was conducted in subgroups regarding to patients drive genes status including EGFR and ALK.
Result:
From Jul. 2009 to Dec. 2016, a total of 159 patients with NSCLC were enrolled. Baseline characteristics were well balanced between 1L and LL groups. The median follow-up time was 10.7 months. Comparing to LL, the median PFS in 1L was significant longer (9.7 months vs 4.1 months, HR=0.28, 95% CI 0.15-0.52, P＜0.0001). Short term effects of ORR and DCR both had improved trends in 1L than LL. Interestingly in subgroups, WT group (median PFS 11.3 vs 3.4 months, HR 0.2, 95% CI 0.08-0.48, P<0.0001) and WT+UN group (median PFS 11.3 vs 3.4 months, HR 0.25, 95% CI 0.12- 0.51, P<0.0001) had better effectiveness as 1L than LL over the whole population. The ORR and DCR had consistently similar response in subgroups comparison (Table 1). There was no unexpected safety issue documented. Figure 1
Conclusion:
Although it was limited in retrospective design, this precious real world evidence indeed exhibited superior clinical effectiveness in first-line use of bevacizumab indicating a better choice rather than later line use, particularly to EGFR&ALK wild type or unknown patients.
